Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTA Centessa Pharmaceuticals	$17.01 -3.0%	$15.28	$9.60 ▼ $19.09	$2.35B	1.48	1.17 million shs	1.13 million shs
HHH Howard Hughes	$75.49 +4.0%	$70.01	$61.40 ▼ $87.77	$4.31B	1.22	389,925 shs	325,295 shs
IBRX ImmunityBio	$2.31 +3.1%	$2.66	$1.83 ▼ $7.48	$2.12B	0.12	9.55 million shs	9.52 million shs
TSHA Taysha Gene Therapies	$3.00 +4.5%	$2.63	$1.05 ▼ $3.31	$616.08M	0.98	2.57 million shs	9.09 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTA Centessa Pharmaceuticals	-2.97%	-5.76%	+9.25%	+32.17%	+39.31%
HHH Howard Hughes	+3.98%	+2.40%	+7.49%	+13.27%	+3.26%
IBRX ImmunityBio	+3.12%	-9.41%	-22.74%	-8.70%	-47.50%
TSHA Taysha Gene Therapies	+4.53%	+2.04%	+11.52%	+9.09%	+32.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTA Centessa Pharmaceuticals	2.1641 of 5 stars	3.5	1.0	1.5	2.5	0.6
HHH Howard Hughes	2.332 of 5 stars	1.3	4.0	3.5	3.3	1.3
IBRX ImmunityBio	2.5223 of 5 stars	3.6	1.0	3.2	1.7	0.6
TSHA Taysha Gene Therapies	3.4165 of 5 stars	4.5	2.0	2.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTA Centessa Pharmaceuticals	3.00	Buy	$28.10	65.20% Upside
HHH Howard Hughes	2.67	Moderate Buy	$80.33	6.42% Upside
IBRX ImmunityBio	3.20	Buy	$10.75	365.37% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$8.29	176.19% Upside

Current Analyst Ratings Breakdown

Latest TSHA, HHH, IBRX, and CNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00
8/13/2025	TSHA Taysha Gene Therapies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$7.50 ➝ $8.00
8/12/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
8/12/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
8/5/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/30/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/25/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/21/2025	CNTA Centessa Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/11/2025	TSHA Taysha Gene Therapies	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/8/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/1/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTA Centessa Pharmaceuticals	$6.85M	332.53	N/A	N/A	$2.58 per share	6.59
HHH Howard Hughes	$1.75B	2.56	$10.08 per share	7.49	$47.55 per share	1.59
IBRX ImmunityBio	$14.74M	148.14	N/A	N/A	($0.60) per share	-3.85
TSHA Taysha Gene Therapies	$8.10M	79.52	N/A	N/A	$0.91 per share	3.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.79	N/A	N/A	N/A	N/A	-40.39%	-29.87%	11/11/2025 (Estimated)
HHH Howard Hughes	$200.55M	$4.57	16.52	82.05	N/A	12.85%	10.51%	3.15%	N/A
IBRX ImmunityBio	-$413.56M	-$0.48	N/A	N/A	N/A	-648.57%	N/A	-113.86%	11/11/2025 (Estimated)
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,144.97%	-78.44%	-44.82%	N/A

Latest TSHA, HHH, IBRX, and CNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.38	-$0.03	-$0.38	$0.63 million	N/A
8/12/2025	Q2 2025	TSHA Taysha Gene Therapies	-$0.07	-$0.09	-$0.02	-$0.09	$1.61 million	$1.99 million
8/5/2025	Q2 2025	IBRX ImmunityBio	-$0.10	-$0.10	N/A	-$0.10	$21.95 million	$26.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HHH Howard Hughes	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTA Centessa Pharmaceuticals	0.32	10.11	10.12
HHH Howard Hughes	1.85	1.18	1.18
IBRX ImmunityBio	N/A	4.11	3.98
TSHA Taysha Gene Therapies	0.17	12.48	12.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTA Centessa Pharmaceuticals	82.01%
HHH Howard Hughes	93.83%
IBRX ImmunityBio	8.58%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
CNTA Centessa Pharmaceuticals	7.09%
HHH Howard Hughes	33.00%
IBRX ImmunityBio	76.79%
TSHA Taysha Gene Therapies	3.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTA Centessa Pharmaceuticals	200	133.91 million	124.42 million	Optionable
HHH Howard Hughes	608	59.40 million	39.80 million	Optionable
IBRX ImmunityBio	590	945.26 million	219.39 million	Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable

TSHA, HHH, IBRX, and CNTA Headlines

Recent News About These Companies

Critical Analysis: Taysha Gene Therapies (NASDAQ:TSHA) and Targeted Medical Pharma (OTCMKTS:TRGM)

August 19, 2025 | americanbankingnews.com

FY2025 Earnings Forecast for TSHA Issued By Chardan Capital

August 19, 2025 | marketbeat.com

FY2025 Earnings Estimate for TSHA Issued By Chardan Capital

August 18, 2025 | americanbankingnews.com

Cantor Fitzgerald Issues Negative Forecast for TSHA Earnings

August 17, 2025 | marketbeat.com

FY2025 EPS Forecast for Taysha Gene Therapies Cut by Analyst

August 16, 2025 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Analyst Upgrade

August 15, 2025 | marketbeat.com

Wells Fargo & Company Increases Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $8.00

August 15, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $8.00

August 15, 2025 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $10.00

August 14, 2025 | marketbeat.com

Taysha Gene Therapies price target raised to $14 from $11 at Canaccord

August 13, 2025 | msn.com

4TSHA : A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through...

August 13, 2025 | benzinga.com

Taysha Gene Therapies (NASDAQ:TSHA) Issues Earnings Results

August 13, 2025 | marketbeat.com

Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...

August 13, 2025 | finance.yahoo.com

XTX Topco Ltd Takes $282,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

August 13, 2025 | marketbeat.com

Taysha Gene Therapies price target raised to $10 from $9 at Chardan

August 13, 2025 | msn.com

Taysha plans pivotal TSHA-102 trial enrollment in Q4 2025, extends cash runway to 2028

August 13, 2025 | msn.com

What's Next: Taysha Gene Therapies's Earnings Preview

August 13, 2025 | benzinga.com

Taysha Gene Therapies Advances Rett Syndrome Trials

August 12, 2025 | tipranks.com

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates

August 12, 2025 | zacks.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Taysha Gene Therapies, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 12, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA, HHH, IBRX, and CNTA Company Descriptions

Centessa Pharmaceuticals NASDAQ:CNTA

$17.01 -0.52 (-2.97%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$17.47 +0.46 (+2.73%)

As of 08/22/2025 07:57 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Howard Hughes NYSE:HHH

$75.49 +2.87 (+3.95%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$75.57 +0.08 (+0.11%)

As of 08/22/2025 07:35 PM Eastern

Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.

ImmunityBio NASDAQ:IBRX

$2.31 +0.07 (+3.13%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.32 +0.00 (+0.22%)

As of 08/22/2025 07:57 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Taysha Gene Therapies NASDAQ:TSHA

$3.00 +0.13 (+4.53%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.01 +0.01 (+0.30%)

As of 08/22/2025 07:37 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time